Human visceral adipose tissue and the plasminogen activator inhibitor type 1

International Journal of Obesity

Volumn 31, Issue 11, 2007, Pages 1671-1679

  Lindeman, J H N ^a   Pijl, H ^a   Toet, K ^b   Eilers, P H C ^a   Van Ramshorst, B ^c   Buijs, M M ^a   Van Bockel, J H ^a   Kooistra, T ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Inflammation; PAI 1; TNF ; Visceral fat

Indexed keywords

ACIPIMOX; FATTY ACID; GROWTH HORMONE; INTERLEUKIN 1; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; IN VITRO STUDY; INTRAABDOMINAL FAT; MALE; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RNA ANALYSIS; STATISTICAL SIGNIFICANCE;

ADIPOSITY; ADULT; ANTHROPOMETRY; CYTOKINES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35648960389     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803650     Document Type: Article

References (38)

1. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome. Links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-2207.
2. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-1364.
3. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.
4. Hanley AJ, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 2004; 53: 1773-1781.
5. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Insulin resistance atherosclerosis study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
6. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
7. Bastard JP, Pieroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother 1999; 53: 455-461.
8. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int Suppl 2003; 84: S65-S68.
9. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212-217.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
11. Kluft C, Jie AF, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988; 59: 329-332.
12. Langendonk JG, Pijl H, Toornvliet AC, Burggraaf J, Frolich M, Schoemaker RC et al. Circadian rhythm of plasma leptin levels in upper and lower body obese women: influence of body fat distribution and weight loss. J Clin Endocrinol Metab 1998; 83: 1706-1712.
13. Hukshorn CJ, Lindeman JH, Toet KH, Saris WH, Eilers PH, Westerterp-Plantenga MS et al. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 2004; 89: 1773-1778.
14. Yudkin JS, Coppack SW, Bulmer K, Rawesh A, Mohamed-Ali V. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo. Thromb Res 1999; 96: 1-9.
15. Kok P, Buijs MM, Kok SW, Van Ierssel IH, Frolich M, Roelfsema F et al. Acipimox enhances spontaneous growth hormone secretion in obese women. Am J Physiol Regul Integr Comp Physiol 2004; 286: R693-R698.
16. Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G, Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999; 19: 1361-1365.
17. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 2000; 1500: 88-96.
18. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
19. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288: H2031-H2041.
20. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212-217.
21. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-1687.
22. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
23. Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-388.
24. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999; 66: 876-888.
25. Buijs MM, Romijn JA, Burggraaf J, De Kam ML, Cohen AF, Frolich M et al. Growth hormone blunts protein oxidation and promotes protein turnover to a similar extent in abdominally obese and normal-weight women. J Clin Endocrinol Metab 2002; 87: 5668-5674.
26. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002; 18: S5-S9.
27. Chan DC, Barrett HP, Watts GF. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 2004; 4: 227-246.
28. Bastard JP, Bruckert E, Robert JJ, Ankri A, Grimaldi A, Jardel C et al. Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? Int J Obes Relat Metab Disord 1995; 19: 836-838.
29. Silveira A. Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes 2001; 109: S527-S532.
30. Gurlek A, Bayraktar M, Kirazli S. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 2000; 23: 88-92.
31. Scelles V, Raccah D, Alessi MC, Vialle JM, Juhan-Vague I, Vague P. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabete Metab 1992; 18: 38-42.
32. Kakafika AI, Liberopoulos EN, Karagiannis A, Athyros VG, Mikhailidis DP. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol 2006; 4: 175-183.
33. Lemieux I, Pascot A, Tchernof A, Bergeron J, Prud'homme D, Bouchard C et al. Visceral adipose tissue and low-density lipoprotein particle size in middle-aged versus young men. Metabolism 1999; 48: 1322-1327.
34. Milosavljevic D, Griglio S, Le Naour G, Chapman MJ. Preferential reduction of very low-density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages. Atherosclerosis 2001; 155: 251-260.
35. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138: 217-225.
36. Frayn KN. Visceral fat and insulin resistance - causative or correlative? Br J Nutr 2000; 83: S71-S77.
37. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 23: 1262-1268.
38. Agarwal N, Sharma BC. Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol Res 2005; 33: 92-96.